How two common medications became one $455M specialty pill

Вимово (Vimovo)

This story was co-published with The Atlantic. Everything happened so fast as I walked out of the doctor’s exam room. I was tucking in my shirt and wondering if I’d asked all my questions about my injured shoulder when one of the doctor’s assistants handed me two small boxes of pills. “These will hold you over…

One thought on “How two common medications became one $455M specialty pill

  1. Not only is the hybrid product an over priced scam, but the company restructured to Ireland, hence the whole profits are a tax dodge too.

Comments are closed.